Corporate News Report – Creative Medical (CELZ)
Market Performance Snapshot
| Metric | Value | Context |
|---|---|---|
| Price (06:36 PM CET, Wed 21 Oct 2026) | USD 0.74 | Current trading price on major exchanges |
| Shares Outstanding | 6.6 million | Current supply of CELZ shares |
| Market Capitalisation | USD 4.8 million | Derived from current price × outstanding shares |
| 24‑Hour Trading Volume | USD 305.6 k | Total value of shares traded in the last 24 hours |
| Year‑End Performance (last month) | -24.91 % | Decline since the end of last month |
| 200‑Day Simple Moving Average | USD 1.63 | Average price over the past 200 trading days |
| 52‑Week High | USD 6.25 (28 Oct 2025) | Peak price reached in the last 52 weeks |
| 52‑Week Low | USD 0.62 (3 Aug 2026) | Lowest price in the last 52 weeks |
The stock experienced a 4.3 % gain during the 24‑hour period ending at 06:36 PM Central Europe on Wednesday, 21 October 2026, reflecting renewed investor interest amid recent positive clinical developments.
Recent Clinical Milestone
Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) announced encouraging results from a pilot study of its Ultrasome™ cell‑free regenerative medicine platform aimed at treating knee osteoarthritis. The six‑month, open‑label investigation enrolled 30 patients and yielded the following key findings:
| Outcome | Result |
|---|---|
| Clinical response (defined criteria) | 93 % of participants met predefined thresholds |
| Pain score reduction | Average decrease of approximately 66 % |
| Biomarker changes | Significant reductions in markers of cartilage breakdown and inflammation |
| Safety profile | No serious adverse events reported during the follow‑up period |
These data support the proposed mechanism of action for Ultrasome™ and underscore its potential advantages for future manufacturing and distribution. Although the platform remains unapproved for any indication, the results are expected to strengthen the case for further development and to inform forthcoming peer‑reviewed publications.
Comparative Stock Activity (Last 24 Hours)
| Ticker | Current Price | % Change | Market Cap | Recent Company News |
|---|---|---|---|---|
| Game Your Game (GYGY) | USD 0.41 | +5.13 % | USD 5.5 m | Launched GameGolf Affiliate Program, targeting golf creators and professionals across the US, Canada, UK, and Ireland. |
| Taoweave (TWAV) | USD 1.46 | +2.08 % | USD 5.6 m | No specific announcement; shares rose modestly. |
| Healthcare Triangle (HCTI) | USD 0.41 | +8.24 % | USD 5.5 m | Secured six new client engagements for its Teyame AI‑enabled customer‑engagement services; projected modest annual run‑rate revenue. |
| Imunon (IMNN) | USD 1.05 | +2.02 % | USD 5.5 m | Sold rights to ThermoDox® to VoxelDox Therapeutics, retaining equity and future royalties while refocusing on its lead clinical program. |
| Traws Pharma (TRAW) | USD 0.37 | +2.70 % | USD 5.6 m | Filed proxy statement for a special meeting to approve a reverse stock split (1‑for‑8 to 1‑for‑15) and potential adjournment. |
The comparative table highlights how Creative Medical’s recent clinical data have positioned it favorably against peers that are experiencing varied market movements and strategic initiatives.
Corporate Profile – Creative Medical Technology Holdings, Inc.
- Headquarters: Phoenix, United States
- Business Focus: Commercial‑stage biotechnology with expertise in immunology, urology, neurology, and orthopedics.
- Core Technology: Adult stem‑cell treatments and interrelated regenerative technologies for multiple therapeutic indications.
- Strategic Vision: Develop scalable, cell‑free regenerative platforms (e.g., Ultrasome™) to enhance manufacturing efficiency, distribution, and patient access while advancing a robust pipeline across key therapeutic areas.
Analyst Commentary
The 4.3 % uptick in CELZ shares coincides with the publication of a high‑impact pilot study that demonstrates both efficacy and safety in a clinically relevant setting. Investors are likely to view the data as a catalyst for future regulatory submissions, potentially justifying a revaluation of the company’s market cap. The 200‑day moving average remains above the current price, suggesting short‑term support, while the 52‑week low indicates recent volatility. Stakeholders should monitor the company’s progress toward formal clinical trials and regulatory approvals, as these milestones will be decisive for long‑term investor confidence.
Prepared by the Corporate News Desk
